Evaluation of BEMA® Buprenorphine NX for Buprenorphine Induction of Opioid Dependent Subjects

Phase 3

Withdrawn

• Conditions: Opioid Dependence
• Interventions: Drug: Buprenorphine and naloxone

• Registration Number: NCT01713803
• Lead Sponsor: BioDelivery Sciences International

Brief Summary

This is a randomized, double blind, placebo controlled study in opioid dependent subjects. Subjects meeting entry criteria will be treated with multiple doses of B-BNX or B-Placebo, with non-responders rescued within 6 hours. Open treatment B-BNX will be administered as follow-up therapy. Clinical efficacy assessments include the clinical opioid withdrawal scale (COWS), subject-rated assessments, and a urine drug screen.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-10-19
• Study First Submitted QC: 2012-10-23
• Study First Posted: 2012-10-25
• Status Verified: 2017-05
• Primary Completion: 2017-05-01
• Study Completion: 2017-05-01
• Last Update Submitted: 2017-05-02
• Last Update Posted: 2017-05-04

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Signed informed consent obtained prior to any study procedure being performed
• Subject is a male or non-lactating female with a negative urine pregnancy test
• Subject is aged 18 to 65 years, inclusive
• Current diagnosis of opioid dependence or addiction per the Diagnostic and Statistical Manual of Mental Disorders - 4th edition (text revision) (DSM-IV-TR) criteria including physical dependence on opioids
• Daily short-acting opiate use of at least 60 mg morphine equivalent no opioid use for at least 12 hours prior to Screening with positive opiate result on urine drug screen
• Clinical opioid withdrawal scale (COWS) score ≥9
• Subject is in good general health in the judgment of the Investigator as determined from the physical and oral examination findings.

Exclusion Criteria

• Use of a long-acting opioid within the last 72 hours

• Use of an investigational drug or device within the last 30 days

• History of hypersensitivity, allergy, or intolerance to buprenorphine, naloxone, or related drugs

• Immediate suicidal risk, as determined by meeting any of the following:

  1. History of suicidal ideation ≤ 3 months prior to Baseline with a score of 4 (intent to act) or 5 (specific plan and intent) on the eC-SSRS
  2. History of suicidal behavior ≤1 year prior to Baseline (actual attempt, interrupted attempt, aborted attempt and/or preparatory acts/behavior) on the eC-SSRS

• A history or current evidence of any clinically significant disorder or any other condition which in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
buprenorphine and nalaxone	Buprenorphine and naloxone	-
Sugar pill	Buprenorphine and naloxone	-

Primary Outcome Measures

Name	Time	Method
The mean change in clinical opioid withdrawal scale (COWS) total score from Baseline to 6 hours following the initial dose

Secondary Outcome Measures

Name	Time	Method
The percentage of subjects with a negative result on the urine drug screen at Day 7
The percentage of subjects with a clinical opioid withdrawal scale (COWS) total score ≤4 at 6 hours after the initial study drug dose